COGT NASDAQ
Cogent Biosciences, Inc.
1W: -4.0%
1M: -10.4%
3M: -14.1%
YTD: -5.2%
1Y: +561.0%
3Y: +176.6%
5Y: +314.1%
$32.92
+1.68 (+5.36%)
Weekly Expected Move ±3.6%
$30
$32
$33
$34
$35
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$5.6B
52W Range4.75-43.73
Volume1,803,868
Avg Volume2,007,324
Beta0.37
Dividend—
Analyst Ratings
Company Info
CEOAndrew R. Robbins
Employees205
SectorHealthcare
IndustryBiotechnology
IPO Date2018-03-29
Websitecogentbio.com
200 Cambridge Park Drive
Waltham, MA 02140
US
Waltham, MA 02140
US
617 945 5576
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Latest News
Cogent Biosciences reports Q1 results
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
Cogent Biosciences (NASDAQ:COGT) Shares Cross Above Fifty Day Moving Average – Should You Sell?
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Ferrante Karen Jean | A-Award | 686 | $35.24 | 2026-04-01 |
| Fairmount Funds Mana | C-Conversion | 7,000,000 | — | 2026-03-31 |
| Fairmount Funds Mana | S-Sale | 7,000,000 | $34.66 | 2026-03-31 |
| Fairmount Funds Mana | C-Conversion | 28,000 | — | 2026-03-31 |
| Fairmount Funds Mana | S-Sale | 3,500,000 | $36.40 | 2026-01-22 |